Purpose
To support a Phase 3 trial of tafenoquine for the radical cure of P. vivax malaria to enable licensure in India.
Grantee
Division
Global Health
Date
NOVEMBER 2023
Region served
ASIA
Committed amount
$3,674,833
Grant topic
Malaria
Duration (months)
50
Grantee location
Geneva, Switzerland
Related work
More about our financials
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.